11/21
07:07 am
nvcr
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma [Yahoo! Finance]
Low
Report
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma [Yahoo! Finance]
11/21
07:05 am
nvcr
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
Low
Report
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
11/21
07:00 am
nvcr
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
Low
Report
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
10/31
08:35 am
nvcr
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
High
Report
NovoCure Limited (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
10/30
07:02 am
nvcr
Novocure Appoints Christoph Brackmann as Chief Financial Officer
Medium
Report
Novocure Appoints Christoph Brackmann as Chief Financial Officer
10/30
07:00 am
nvcr
Novocure Reports Third Quarter 2024 Financial Results
Low
Report
Novocure Reports Third Quarter 2024 Financial Results
10/16
11:01 am
nvcr
NovoCure: There Is Still More Upside [Seeking Alpha]
Low
Report
NovoCure: There Is Still More Upside [Seeking Alpha]
10/16
07:39 am
nvcr
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $30.00 price target on the stock, up previously from $24.00.
High
Report
NovoCure Limited (NASDAQ: NVCR) was upgraded by analysts at HC Wainwright from a "neutral" rating to a "buy" rating. They now have a $30.00 price target on the stock, up previously from $24.00.
10/15
04:43 pm
nvcr
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
High
Report
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
10/1
01:17 pm
nvcr
NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at Evercore ISI from $21.00 to $18.00. They now have an "in-line" rating on the stock.
Low
Report
NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at Evercore ISI from $21.00 to $18.00. They now have an "in-line" rating on the stock.
10/1
07:00 am
nvcr
Novocure to Report Third Quarter 2024 Financial Results
Medium
Report
Novocure to Report Third Quarter 2024 Financial Results
9/9
07:00 am
nvcr
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
Low
Report
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
9/3
07:00 am
nvcr
Novocure Announces Planned CEO Transition
High
Report
Novocure Announces Planned CEO Transition
8/28
07:00 am
nvcr
Novocure to Participate in 2024 Wells Fargo Healthcare Conference
Medium
Report
Novocure to Participate in 2024 Wells Fargo Healthcare Conference